Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Midostaurin

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 151,021Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Dr Reddy's Generic Midostaurin Receives Approval in US
    Dr Reddy's Generic Midostaurin Receives Approval in US

    28 Jun 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215921

    FDA
    28 Jun 2024
    Share Share
    Lotus's Generic Midostaurin Receives Approval in the U.S.
    Lotus's Generic Midostaurin Receives Approval in the U.S.

    24 Aug 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215834

    FDA
    24 Aug 2022
    Share Share
    Actinium Evaluates Primary Endpoint of Pivotal Phase 3 SIERRA Trial
    Actinium Evaluates Primary Endpoint of Pivotal Phase 3 SIERRA Trial

    13 Dec 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-inc-announces-greater-difference-of-approximately-5x-for-iomab-b-vs-control-arm-in-the-number-of-patients-potentially-evaluable-for-the-primary-endpoint-of-the-pivotal-phase-3-sierra-trial-at-the-63rd-as-301442794.html

    PRNEWSWIRE
    13 Dec 2021
    Share Share
    NICE Recommends First Treatment for Rare Blood Disorder
    NICE Recommends First Treatment for Rare Blood Disorder

    20 Aug 2021

    // GLOBALGENES

    https://globalgenes.org/2021/08/19/nice-recommends-first-treatment-for-rare-blood-disorder/

    GLOBALGENES
    20 Aug 2021
    Share Share
    NICE recommends first treatment for rare blood disorder
    NICE recommends first treatment for rare blood disorder

    19 Aug 2021

    // NICE

    https://www.nice.org.uk/news/article/nice-recommends-first-treatment-for-rare-blood-disorder

    NICE
    19 Aug 2021
    Share Share
    Blueprint challenges Novartis with new Ayvakit nod
    Blueprint challenges Novartis with new Ayvakit nod

    18 Jun 2021

    // Angus Liu FIERCEPHARMA

    https://www.fiercepharma.com/marketing/blueprint-challenges-novartis-new-ayvakit-nod-blood-disorders-more-competition-to-follow

    Angus Liu FIERCEPHARMA
    18 Jun 2021
    Share Share